Biotheryx
San Diego
About Biotheryx
Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first FDA approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform. Our platform leverages an extensive patent protected and rationally designed library of Cereblon binders that we believe provides us with a differentiated starting point for drug design of molecular glues, bifunctional degraders and hybrid degraders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $134.7M
- Last round: Corporate Round (Apr 2023)
- Website: biotheryx.com
- Phone: (914) 490-5425
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biotheryx-49704 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.